Jordyn O'Leary, PA
Physician Assistant · Scranton, PANPI 1265907851
Payments from drug & device makers
Across 471 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$900
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$802
- Johnson & Johnson$738
- Alkermes, Inc.$530
- Otsuka America Pharmaceutical, Inc.$484
- Neurocrine Biosciences, Inc.$482
- plus $3K from 24 others
What the payments were for
- Food & beverage$7,00298%
- Education$1582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $900 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $802 |
| Johnson & Johnson | 56 | $738 |
| Alkermes, Inc. | 28 | $530 |
| Otsuka America Pharmaceutical, Inc. | 28 | $484 |
| Neurocrine Biosciences, Inc. | 41 | $482 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $463 |
| Teva Pharmaceuticals USA, Inc. | 24 | $431 |
| Bausch Health US, LLC | 17 | $359 |
| Axsome Therapeutics, Inc. | 13 | $243 |
| Eisai Inc. | 14 | $233 |
| Lundbeck LLC | 14 | $195 |
| Vanda Pharmaceuticals Inc. | 11 | $182 |
| Jazz Pharmaceuticals Inc. | 10 | $158 |
| Neos Therapeutics, LP | 11 | $156 |
| Merck | 8 | $127 |
| Novo Nordisk | 6 | $98 |
| Biogen | 6 | $94 |
| Indivior Inc. | 4 | $77 |
| Corium, LLC | 8 | $66 |
| Sunovion Pharmaceuticals Inc. | 6 | $59 |
| Supernus Pharmaceuticals, Inc. | 4 | $58 |
| Almatica Pharma LLC | 3 | $52 |
| Noven Therapeutics, LLC | 2 | $46 |
| Alfasigma USA, Inc. | 2 | $45 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
How this compares
$7,161 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $246,151 |
| Tasimelteon | 12 | $162,897 |
| Austedo XrDeutetrabenazine | 19 | $150,126 |
| VraylarCariprazine Hcl | 104 | $135,670 |
| RexultiBrexpiprazole | 72 | $103,506 |
| AustedoDeutetrabenazine | 13 | $94,711 |
| NuplazidPimavanserin Tartrate | 17 | $85,556 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $25,848 |
| Abilify MaintenaAripiprazole | 11 | $23,159 |
| CaplytaLumateperone Tosylate | 14 | $21,547 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $20,143 |
| AristadaAripiprazole Lauroxil | 11 | $17,406 |
| TrintellixVortioxetine Hydrobromide | 18 | $12,805 |
| BelsomraSuvorexant | 21 | $10,050 |
| Lurasidone Hcl | 36 | $9,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $482 | $246,15117 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $431 | $244,83732 claims |
| AbbVieVraylar | $900 | $135,670104 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $484 | $126,66583 claims |
| Acadia Pharmaceuticals IncNuplazid | $13 | $85,55617 claims |
| Alkermes, Inc.Lybalvi, Aristada | $530 | $37,54923 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $29 | $25,84813 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $802 | $21,54714 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $463 | $12,80518 claims |
| MerckBelsomra | $127 | $10,05021 claims |
| Almatica Pharma LLCSertraline Hcl | $52 | $1,359140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Scranton
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
- Justine RobertsMurrysville$173K
- Allison BoydErie$163K
- Joshua TrbovichWashington$144K
- Daniel TelegaErie$124K
- Alvin KingcadePhiladelphia$101K
- Jeffrey CameronWashington$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.